RPG Life Sciences Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #80 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on RPG Life Sciences Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations:. Q2 FY25 EBITDA: Rs. 47.9 Cr with a margin of 31.5%, up from Rs. 39.1 Cr and 25.5% margin in Q2 FY24.
From RPG Life Sciences Ltd's Q2 FY25 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations:
- Q2 FY25: ₹172.2 Crores
- Q2 FY24: ₹153.6 Crores
- YoY Growth: +12.1%
- Sales Growth by Segments (H1 FY25 vs H1 FY24):
- Domestic Formulations (66% of sales): 10% growth
- API (15% of sales): 14% growth
- International Formulations (19% of sales): 16% growth
- Outlook:
- Focus on scaling up business through comprehensive 7 pillars including innovation, capacity expansion, and talent acquisition (Page 43).
2 more points from RPG Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).
- Modernization and capacity expansion of formulations and API plants highlighted as part of business growth strategy (Page 42).
- State-of-the-art, modern, cost-efficient cGMP compliant plants approved by EU/PICS/TGA with ~2X higher capacity targeted for niche-focused R&D pipeline (Page 43).
- Plant modernization and capacity expansion are ongoing transformation projects (Page 11).
2 more points from RPG Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
RPG Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Themis Medicare (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were RPG Life Sciences Ltd Q2 FY25 results?
Revenue from Operations:. Q2 FY25 EBITDA: Rs. 47.9 Cr with a margin of 31.5%, up from Rs. 39.1 Cr and 25.5% margin in Q2 FY24.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
